Clal Biotechnology Industries Ltd. (TASE: CBI) portfolio company Thrombotech Technologies Ltd. reports positive results in the Phase I clinical trial of THR-18 for the treatment of ischemic stroke, pulmonary embolism, heart attacks, and other cardiac issues.
The trial on 40 patients aimed to test the safety of the drug concentration profile in the blood. The trial tested four dosages of the drug and the frequency of the dosages. The trial found no significant side effects related to the drug.
The trial demonstrated that certain dosages of the drug lowered blood pressure, which supported the findings of the preclinical trial and the estimated active mechanism of the drug.
Thrombotech said that it is considering additional treatments on the basis of the trial results. The company added that the drug is still under development.
Clal Biotech owns 41% of Thrombotech, Hadasit Bio Holdings Ltd. (TASE:HDST) owns 35%, and Ofer Hi Tech Ltd.) owns 25%.
Published by Globes [online], Israel business news - www.globes-online.com - on September 7, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010